JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online April 16, 2009, 10.2967/jnumed.108.060756
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koole, M.
Right arrow Articles by Van Laere, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koole, M.
Right arrow Articles by Van Laere, K.

Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging

Michel Koole1, Dewi M. Lewis2, Christopher Buckley2, Natalie Nelissen3, Mathieu Vandenbulcke4, David J. Brooks2,5, Rik Vandenberghe3,6 and Koen Van Laere1

1 Nuclear Medicine, University Hospital and K.U. Leuven, Leuven, Belgium; 2 GE Healthcare Medical Diagnostics Research and Development, Amersham, United Kingdom; 3 Laboratory for Cognitive Neurology, K.U. Leuven, Leuven, Belgium; 4 Psychiatry Department, UZ Leuven, Leuven, Belgium; 5 Division of Neuroscience, Faculty of Medicine, Imperial College London, London, United Kingdom; and 6 Neurology Department, UZ Leuven, Leuven, Belgium


Figure 1
View larger version (32K):
[in this window]
[in a new window]

  		FIGURE 1.  Whole-body time–activity distribution of 18F-GE067 in subject 1 (Table 1), with representative coronal and sagittal slices as indicated on CT view on left. PET image color intensities are expressed as activation concentration (kBq/cm3). Upper row indicates start (min) of whole-body scan.

 

Figure 2
View larger version (76K):
[in this window]
[in a new window]

  		FIGURE 2.  Brain uptake distribution of 18F-GE067 in healthy 64-y-old male subject (top), compared with 68-y-old male AD patient (bottom). Transverse, sagittal, and coronal sections indicate absence of specific gray matter uptake of 18F-GE067 and aspecific uptake in white matter, pons, and thalamus. Images represent standardized uptake value ratios (SUVR) to cerebellar cortex, between 85 and 105 min after injection, obtained from phase I clinical study.

 

Figure 3
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 3.  Mean activity in brain, gallbladder, intestine, liver, and urinary bladder as fraction of total-body activity, at all time points for 6 subjects.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.